Eisai and partner Helsinn secured the FDA's blessing to market Akynzeo, a combination treatment designed to prevent nausea and vomiting among cancer patients undergoing chemotherapy. The long-acting drug combines palonosetron, approved in 2008 and sold by Eisai as Aloxi, with netupitant, a new agent. The former is designed to prevent nausea within the first 24 hours of chemo, while the latter provides relief for up to 5 days afterward. More from FiercePharma